CN Bio Innovations Ltd.. (6/6/23). "Pressemitteilung: CN Bio Appoints Dr. Samantha Macro as Chief Financial Officer". Cambridge.

	Organisation	CN Bio Innovations Ltd.
	Group	CN Innovations (Group)
	Organisation 2	Mestag Therapeutics Ltd.
	Product	PhysioMimix® Organs-on-Chips system
	Product 2	BIOTECH
	Person	Macro, Samantha (CN Innovations 202306– CFO at CN Bio before Mestag Therapeutics + Horizon Discovery + Johnson Matthey)
	Person 2	Brooks, Paul (CN Innovations 202212– CEO joined as CBO 5/22 before Horizon Discovery + Oxford Genetics + Sigma-Aldrich)

Key executive appointment provides extensive financial industry experience as the Company implements ambitious global growth strategy

CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced that it has appointed Dr. Samantha Macro as Chief Financial Officer. Samantha joins CEO, Dr. Paul Brooks, on the executive team to guide all key commercial and strategic initiatives, drive revenue and shape CN Bio’s ongoing growth trajectory.

Samantha’s appointment becomes CN Bio’s third leadership-level appointment in the past six months, as the Company continues to scale and strengthen its senior team during this next phase of commercial development. Bringing extensive financial industry experience, including over 15 years in life sciences, Samantha will play a pivotal role in guiding and executing the decisions which will grow the Company’s OOC offerings across key global markets.

Most recently, Samantha was VP of Finance at Mestag Therapeutics, where she was a core part of the leadership team that secured the Company’s successful $45 million seed financing round. Prior to this, Samantha was Global Head of Finance at Horizon Discovery, during which time she supported strategic and M&A initiatives while preparing for a NASDAQ listing. She was a core part of the team that supported the pre- and post-acquisition associated with the sale of the Group to PerkinElmer (now Revvity). She has also held various leadership roles at the Johnson Matthey Pharma division, and across multiple innovative medicine units at AstraZeneca. Ahead of transitioning into life sciences, Samantha qualified as a chartered accountant at PwC and held senior roles at PwC and Aviva. She has an MBA and PhD from Loughborough University Business School.

Dr. Samantha Macro, CFO, CN Bio, commented: “CN Bio’s OOC solutions are disruptive within the sector; capable of accurately and efficiently predicting human responses to medicines. As its growing range of products and services continue to gain traction across global markets, I look forward to working closely with the leadership team and leveraging my commercial insight to push the Company to reach its full potential.”

Dr. Paul Brooks, CEO, CN Bio, said: “I look forward to working closely with Samantha, who brings great experience and will be a strong addition to CN Bio’s team. She has a proven track record in fundraising and will bring valuable M&A experience to the Company. We have reached a critical phase in the commercialisation of our OOC technology, and Samantha will be instrumental in reaching our business goals and executing our continued growth strategy.”

ENDS

Notes to Editors

Dr Samantha Macro, Chief Financial Officer at CN Bio
For a high-resolution image please contact Zyme Communications.

For further information please contact:

Zyme Communications
Lily Jeffery
Tel: +44(0)7891477378
Email: lily.jeffery@zymecommunications.com

CN Bio

Dr Sarah Payne, Product Marketing Manager
Email: sarah.payne@cn-bio.com

About CN Bio https://cn-bio.com/

CN Bio is a leading organ-on-a-chip (OOC) company that offers a portfolio of products and services to optimise the accuracy and efficiency of bringing new medicines to market; providing significant savings in cost and time to drug discovery and development pipelines. With more than a decade of research and development experience in multi-organ microphysiology, CN Bio aims to transform the way human-relevant pre-clinical data is generated through the development of the most complete model of the human “Body-on-a-Chip” in the laboratory.

The Company’s range of lab-benchtop PhysioMimix™ microphysiological systems (MPS) enable researchers to model human biology in the lab through rapid and predictive 3D human tissue-based studies that harness microfluidic technology to provide nutrients and mimic blood flow. The technology bridges the gap between traditional cell culture and human studies, advancing towards the simulation of human biological conditions to support the accelerated and more efficient development of new therapeutics, whilst reducing the dependence on animal model usage.

CN Bio’s MPS support researchers that require reliable, data-rich, in vitro studies, to uncover novel mechanistic insights into a broad range of biological processes across healthy and diseased cell-types, in addition to identifying novel therapeutic targets and investigating drug efficacy, pharmacokinetics and potential toxicity.

The Company’s next-generation OOC assays span a range of organ types, including lung, liver and gut. Single organs can be linked together into multi-organ systems to simulate processes such as drug absorption and metabolism, or to understand interactions between organs, such as inflammation.

Harnessing these assays, its portfolio of MPS, 3D validated cells, compatible consumable plates and research services have been developed to address drug development bottlenecks across a range of therapeutic areas, including metabolic and infectious diseases, oncology, and inflammation.

CN Bio’s headquarters and laboratories are based in Cambridge, UK, with an international network of distributors.

Follow CN Bio on LinkedIn @CN Bio and Twitter @CN_Bio.

Record changed: 2024-01-20